Recent Updates
Recently added Catalysts
FULC

Fulcrum Therapeutics to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

Key Takeaway: CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2022 financial resul
Price reaction · baseline $5.8 (2022-11-01 close) · hit after-hours · 1 other FULC headline(s) in the window, move may be shared
day 0 close · peak
-4.8%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
15.6%
average across 6 past catalysts
Cash runway
~59 mo
Minimal dilution risk
Lead asset
Pociredir
Phase 2 · Sickle Cell Disease

Full Press Release Details

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
U.S. Dial-in Number: 833-634-2546
International Dial-in Number: 412-902-4190
All participants should ask to be connected to the Fulcrum Therapeutics conference call.
Replay U.S. Dial-in Number: 877-344-7529
Replay Canada Dial-In Number: 855-669-9658
Replay International Dial-in Number: 412-317-0088
Replay Access Code: 2495296
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Stern Investor Relations, Inc.
Last updated: Nov 2, 2022